





Traumatic injury is one of the leading causes of death, with uncontrolled hemorrhage from coagulation dysfunction
as one of the main potentially preventable causes of the mortality. Hypothermia, acidosis, and resuscitative
hemodilution have been considered as the significant contributors to coagulation manifestations following
trauma, known as the lethal triad. Over the past decade, clinical observations showed that coagulopathy may
be present as early as hospital admission in some severely injured trauma patients. The hemostatic dysfunction is
associated with higher blood transfusion requirements, longer hospital stay, and higher mortality. The recognition
of this early coagulopathy has initiated tremendous interest and effort in the trauma community to expand our
understanding of the underlying pathophysiology and improve clinical treatments. This review discusses the
current knowledge of coagulation complications following trauma.
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Background
Traumatic injury remains one of the leading causes of
death, accounting for about 40% of prehospital death
[1, 2]. Uncontrolled hemorrhage from coagulation dys-
function is one of the main potentially preventable
causes of the mortality in both civilian and military set-
tings [3–7]. Hypothermia, acidosis, and resuscitative
hemodilution have been considered as the significant
contributors to coagulation dysfunction after trauma.
Over the past decade, clinical observations around the
globe have independently shown that coagulopathy may
be present as early as hospital admission in some
trauma patients. The hemostatic manifestation is asso-
ciated with increased blood transfusion requirements,
longer hospital stay, and higher mortality [7–11]. The
recognition of this early coagulopathy leads to the use
of new terminology and proposed hypotheses [8, 12,
13]. However, to date, our understanding of the under-
lying mechanisms remains incomplete. This review
summarizes the current knowledge of coagulation com-
plications following trauma.
Coagulation process
Blood coagulation is an important physiological process,
including a series of physical, biochemical and cellular
responses after various stimuli. The essence of the
process is the production of fibrin clots from fibrinogen
(factor I), and thrombin plays a central role catalyzing
the reaction [14]. Biochemically, blood clotting is initi-
ated via the intrinsic and/or extrinsic pathways. The
two pathways converge to form a common pathway to
generate thrombin. The intrinsic pathway, or contact
activation pathway, consists of the activations of factor
VIII, IX, X, XI, XII and Xa complex, resulting in throm-
bin generation from precursor prothrombin (factor II).
The extrinsic pathway is triggered by plasma factor
VIIa binding with tissue factor (factor III) released from
the injury sites. The factor VIIa/tissue factor complex,
once produced, activates additional factor VII, initial
thrombin, factor Xa complex, and platelets, resulting in
the exponential thrombin burst for rapid clot formation
[15]. This classic cascade model provides a biochemical
description of the coagulation process and the basis for
clinical assessments of coagulation; but it is now con-
sidered incomplete because it does not take into con-
sideration the coagulation inhibition in plasma. Clinical
standard plasma tests of prothrombin time (PT) and
activated partial thromboplastin time (aPTT) reflect the
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overall enzyme activities involved in the extrinsic and
intrinsic pathways, respectively.
The formation of fibrin clots is counterbalanced by
its inhibitory and anti-coagulation processes. Circulat-
ing antithrombin III inhibits factor Xa and thrombin,
with 2000-fold amplified effects by heparin [16]. Tissue
factor pathway inhibitor inhibits factor Xa and eliminates
the contribution of the extrinsic pathway to clot formation.
Activated protein C, the product of the thrombomodulin-
thrombin complex, inactivates prothrombinase and the in-
trinsic pathway [17]. In addition, fibrin clots, once
formed, are subject to fibrinolysis by plasmin. Plasmin
is generated from inactive protein plasminogen via
tissue-type plasminogen activator (tPA) [18]. The activ-
ity of tPA can be inhibited by plasminogen activator inhib-
itors (PAI) [19, 20]. The fibrinolytic system is regulated
through the generation of plasmin from the activities of
tPA, PAI and an antiplasmin inhibitor. Under any normal
physiological state, the blood coagulation status is a dy-
namic process and is the balance of clot formation, anti-
coagulation and fibrinolysis.
Another description of the coagulation process is a cell-
based model of hemostasis [21]. This model considers the
process as three overlapping phases: initiation, amplifica-
tion and propagation. All three phases are regulated by
the properties of cell surfaces, receptors, and coagulation
proteins. This model provides the basis of viscoelastic
tests, such as thromboelastography (TEG) and rotational
thromboelastometry (ROTEM), to profile the dynamic
nature of the clotting process and guide resuscitation
practice [22, 23].
Coagulation tests
Early traumatic coagulopathy has been defined by different
measurements, including standard plasma tests of PT,
aPTT, thrombin time, platelet counts, fibrinogen levels,
and blood viscoelastic tests of clotting amplitudes and clot
lysis [8, 22, 24–28]. At present,, there is no standard or
globally accepted assay for diagnosing early traumatic co-
agulopathy, although prolonged PT has been used by
many investigators to study trauma-induced coagulopathy.
Compared to plasma PT and aPTT, TEG and ROTEM
provide more comprehensive description of coagulation
status, including measurements of clotting formation
time, clotting speed, clot strength, and fibrinolysis. This
advantage has made its increased use in the diagnosis of
trauma-induced coagulopathy, the prediction of massive
transfusion and for guiding the transfusion of blood
products [23, 29]. However, TEG and ROTEM have lim-
ited sensitivity in reflecting platelet dysfunction and
moderate fibrinolysis [23, 30, 31]. A randomized con-
trolled trial is warranted to validate TEG or ROTEM’s
role in guiding massive transfusion protocols in trauma
patients.
Coagulation complications after trauma
After traumatic injury, coagulation, anti-coagulation
and fibrinolysis are disproportionally affected, leading
to impaired hemostasis. The alterations have been
found to be dynamic and multifactorial. For simplicity,
it is helpful to describe the changes in three phases: 1)
acute post-trauma phase, which occurs shortly, within
hours, after trauma injury; 2) resuscitation phase, which
occurs 24–48 h post trauma, when various resuscitation
fluids may be used; and 3) later phase, which occurs
days after trauma injury.
Acute post-trauma phase
Trauma-related coagulopathy has been considered to
be primarily due to blood loss from injury, hemodilu-
tion from aggressive resuscitation, and the development
of hypothermia and acidosis [32, 33]. During the last
decade, clinical studies have shown that prolonged PT
and aPTT prothrombin time were observed in some
trauma patients at emergency room admission [8–10].
This hemostatic complication is independently associ-
ated with increased blood transfusion requirement and
higher mortality than those with similar injury but
without coagulopathy [8–10]. The recognition of this
early coagulopathy prior to fluid resuscitation has initi-
ated tremendous interest and effort to expand our
understanding of trauma-related coagulopathy. As the
results, new terminology has been created to describe
the early developed coagulopathy, such as acute coagulop-
athy of trauma (ACT), acute traumatic coagulopathy
(ATC), trauma induced coagulopathy (TIC), and early
coagulopathy of trauma. Hypotheses have also been pro-
posed to attempt to explain the underlying mechanisms.
One hypothesis is consumptive coagulopathy, a pheno-
typic variation of classic disseminated intravascular co-
agulation (DIC) [34]. Immediately after trauma, trauma
injury exposes tissue factor, which is normally present
inside tissues, to the circulation and initiates thrombin
generation and clot formation. Platelets are activated
through a network of regulated interconnecting cellular
signals, including collagen in the sub-endothelial matrix
binding to glycoprotein VI, von Willebrand Factor
(vWF) and glycoprotein Ib [15]. The activation of plate-
lets amplifies thrombin generation and the clotting
process, causing the consumption of the coagulation
factors. The most depleted factors are fibrinogen and
factor V [35]. In addition, fibrinolysis is activated from the
release of tissue plasminogen activator, which converts
plasminogen to plasmin, into the circulation. Conse-
quently, hypocoagulation and hyperfibrinolysis are de-
veloped in trauma patients.
Another hypothesis considers that activated protein C
plays a central role in enhancing anti-coagulation [8, 24,
36, 37]. Based on this hypothesis, following severe
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trauma injury and hypoperfusion, thrombin is gener-
ated and binds thrombomodulin to form activated pro-
tein C. Activated protein C exerts its anticoagulant role
by inhibiting factor Va and VIIIa and its hyperfibrinoly-
tic role by inhibiting plasminogen activator inhibitor.
Thus, activated protein C accounts for the hypocoagu-
lation and hyperfibrinolysis characteristics observed in
some trauma patients.
The third hypothesis focuses on trauma-induced neuro-
hormonal and endothelial responses [38, 39]. Tissue injury
from trauma induces sympathoadrenal responses and
catecholamine release. Circulating catecholamine damages
the endothelial glycocalyx and converts the endothelial
function from antithrombotic to prothrombotic for local
hemostasis. There is also a counterbalance mechanism of
the anticoagulation and fibrinolytic responses in the blood
to prevent this local response from extending beyond
injury sites. However, this counterbalance mechanism is
amplified after severe trauma injury, resulting in hypocoa-
gulation and hyperfibrinolysis observed in some trauma
patients.
To date, debates and controversies remain in these hy-
potheses [7, 13, 40]. Nevertheless, traumatic injury and
shock related hypoperfusion have been widely accepted
as the two important initiators of the early coagulopathy
following trauma [24, 32, 41]. The severity of the trauma
and the duration of shock appear to be positively related
to the severity of coagulation dysfunction.
Resuscitation phase
The resuscitation phase covers the first few days (i.e.,
24–48 h) after trauma injury. During this phase, meta-
bolic acidosis and hypothermia may develop together
with hemodilution from resuscitation fluids used to im-
prove hemodynamics. These factors may further impair
and amplify the already existing coagulopathy from the
trauma injury [42–44].
Metabolic acidosis
Clinical acidosis is commonly observed in trauma pa-
tients due to hypo-perfusion from massive blood loss.
Impaired clotting enzyme activities have demonstrated
the effects of acidosis on coagulation. Acidotic trauma
patients showed prolonged PT and aPTT and decreased
coagulation factor levels. Quantitatively, when pH was
reduced from 7.4 to 7.0 in vitro, the activities of factor
VIIa and factor VIIa/TF on phospholipid vessels de-
creased by more than 90 and 60%, respectively [45].
When pH was reduced from 7.4 to 7.1 in pigs, thrombin
generation decreased to 47% of the control values [46].
In thrombin generation kinetics, acidosis moderately
inhibited the initiation phase of thrombin generation,
but persistently and dramatically inhibited the propaga-
tion phase [46]. These data showed that acidosis more
severely inhibited the activation of factor V, VIII, IX, X
and the formation of factor Xase and the prothrombi-
nase complex in the propagation phase, compared to the
activation of factor VIIa/tissue factor complex in the ini-
tiation phase [46].
The effects of acidosis on fibrinogen availability and me-
tabolism were investigated in a swine model using stable
isotope infusion and subsequent gas chromatograph mass
spectrometry analysis [47]. Acidosis of pH 7.1 caused a
1.8-fold increase in fibrinogen breakdown rate compared
to the control values but did not affect fibrinogen synthe-
sis rate [47]. The accelerated consumption and unchanged
production suggest a deficit of fibrinogen availability and
support the supplementation of exogenous fibrinogen to
improve hemostasis.
To restore coagulation function impaired by acidosis,
bicarbonate solution was used to neutralize pH in a
swine model after the induction of acidosis [48]. Acid-
osis of pH 7.1 depleted fibrinogen levels and platelets
counts and impaired thrombin generation, clotting
speed and clot strength [48]. The infusion of bicarbonate
solution immediately corrected pH to 7.4. However, bicar-
bonate pH neutralization did not immediately recover the
depleted substrate levels or coagulation dysfunction. Simi-
lar findings were observed when a different pH neutralizer,
tris-hydroxymethyl-aminomethane, was used [49]. These
findings demonstrated that acidosis-induced coagulopa-
thy, once developed, cannot be corrected immediately by
pH neutralization. Thus, the clinical focus of acidosis-
induced coagulopathy should be on prevention instead of
correction.
Hypothermia
The effects of hypothermia on the coagulation process
have been estimated by cold-induced changes in standard
clinical tests. Prolonged PT and aPTT have been shown in
hypothermic patients and experimental animals, as well as
plasma cooled in vitro [50–53]. The in vivo effects of
temperature on thrombin generation kinetics were investi-
gated in a swine model [46]. Hypothermia of 32 °C primar-
ily inhibited the initiation phase of thrombin generation,
involving the formation of factor VII/tissue factor complex
[46]. The thrombin generation propagation phase, how-
ever, was not affected. Thus, compared to those observed
in acidosis, hypothermia impairs the thrombin generation
kinetics differently from acidosis.
Temperature effects on fibrinogen metabolism and
availability were investigated in pigs with stable isotope in-
fusion [54]. Hypothermia of 32 °C decreased fibrinogen
synthesis rate by 50% of the control values, but fibrinogen
breakdown rate remained unchanged [54]. Compared to
the accelerated breakdown and unchanged synthesis by
acidosis, hypothermia affects fibrinogen metabolism via
different mechanisms. However, the decreased production
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and unchanged consumption by hypothermia indicate a
similar outcome as acidosis: a potential deficit in fibrino-
gen availability.
Resuscitation
Following blood loss, fluid resuscitation is a routine clinical
practice to restore tissue perfusion and hemodynamics. A
variety of resuscitation fluids have been used around the
world, with selections depending on availability, cost, and
local clinical experience. Crystalloids, such as normal saline
and lactated Ringer’s (LR) solution, are inexpensive and
have been widely used for resuscitation [55–57]. Normal
saline is a NaCl salt solution with an average pH of 5.0. LR
has an average pH of 6.5 and has similar electrolytes to
plasma, thus is considered as a more physiologically
compatible fluid. In comparative trials of LR and nor-
mal saline in patients undergoing kidney transplant or
aortic aneurysm repair, similar clinical outcomes of
ICU stay, ventilation time, and complication incidence
were observed in patients resuscitated with LR or normal
saline, although patients with normal saline were more
acidotic. In a rat model with moderate hemorrhage (36%
of estimated total blood volume) and simultaneous resus-
citation, normal saline and LR had equivalent survival
rates [58]. However, LR resuscitation resulted in better
survival after a massive hemorrhage (218% of estimated
total blood volume) [58]. In a large animal model with
femur fracture and 60% hemorrhage, normal saline and
LR have similar effects on hemodynamics, oxygen metab-
olism and coagulation [59]. Normal saline required a lar-
ger resuscitation volume and was associated with poor
acid base status and elevated serum potassium [59].
Colloids are highly effective at increasing the intravascu-
lar volume with a small volume increase in the interstitial
space, compared with crystalloids. This volume-expanding
advantage is logistically important in pre-hospital circum-
stances and in far forward battlefield conditions. Different
colloids, such as albumin, gelatin, and hydrozyethyl starch,
have been used clinically [60–63]. Although positive
clinical outcomes have been reported in some clinical tri-
als and animal studies, colloid resuscitation has been asso-
ciated with a reduction in coagulation factors, platelet
dysfunction and hemorrhagic complications [64–66]. In a
swine model with traumatic hemorrhage, Hextend resus-
citation caused severe reductions in coagulation factors,
platelet counts and fibrinogen levels and impaired coagu-
lation based on TEG. Those deteriorations persisted for
the entire 6-h experimental duration,, whereas coagulation
was restored 3 h after LR resuscitation [59].
With the emphasis on limiting crystalloids and increas-
ing blood products, damage control resuscitation has been
increasingly recognized and implemented in trauma care
over the past decade [67–69]. Blood products, such as
fresh frozen plasma (FFP), packed red blood cells (PRBC)
and platelets, have been used for hemostatic resuscitation
and hemodynamic resuscitation. As a proactive approach
in damage control resuscitation, massive transfusion pro-
tocols quickly provide large amounts of blood products to
critically injured and bleeding patients [70]. The selection
and the order of the infusion of blood products in bleed-
ing patients vary at different trauma centers [71, 72]. In
both military and civilian trauma reports, higher ratios of
plasma and platelets to PRBC appear to be more beneficial
with improved survival [73, 74]. However, the use of blood
components is also associated with increased risks in in-
fection and organ failure [75–77]. The optimum ratios
and doses of those blood products are still debatable.
Pharmaceutical hemostatic agents, such as fibrinogen
concentrate, have been used as resuscitation to replen-
ish fibrinogen levels. Among coagulation factors de-
pleted after traumatic injury, fibrinogen is the first to
drop to a critical level [47, 54, 78]. These findings
support the notion of supplementing exogenous fi-
brinogen to restore coagulation function. The clinical
use of fibrinogen concentrate has been shown in surgical
patients to be efficacious, with improved clotting function
and reduced transfusion requirements [79–83]. Large
prospective clinical trials are on-going to investigate the
efficacy of fibrinogen concentrate pre-hospital and in-
hospital use in trauma patients.
Late post-trauma phase
During the late post-trauma phase, the systemic levels of
cytokines and hormones increase, leading to endothelial
cell activation. The activated endothelial cells, circulating
cytokines and thrombin, lead to a slow transition of the
endothelial cell phenotype from antithrombiotic to pro-
thrombotic. The endothelial cell activation also down-
regulates thrombomodulin and fibrinolysis. In addition,
the fibrinogen levels increase several folds due to acute
phase responses. Overall, the coagulation process at this
phase becomes the prothrombotic state, predisposing
patients to venous thromboembolism, which leads to pa-
tients requiring heparin or a newer anticoagulant drug.
Coagulation complications in sepsis
Coagulopathy in sepsis appears to be similar to the pro-
thrombotic state observed in the late phase of trauma,
although it is much less studied compared to trauma.
During sepsis, the coagulation cascade is activated by
inflammatory cytokine release and tissue factor [84–86].
Although the primary source of tissue factor remains un-
clear, it plays a key role in the activation of the coagulation
cascade, via the binding of factor VII and the production
of factor Xa for thrombin generation [86]. Inflammation
also releases platelet activation factor to activate platelets,
providing a surface for thrombin generation. In addition,
pro-inflammatory cytokines are upregulated and play an
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important role in the suppression of anticoagulation. The
enhanced prothrombic state and inhibited anticoagulation
contribute to hypercoagulopathy and the development of
DIC in sepsis [87]. As the severity of sepsis progresses, the
dysfunctional coagulation leads to microvascular throm-
bosis and multiple organ dysfunction syndrome [85, 87].
Widespread intravascular activation of the coagulation
system is the hallmark of DIC from various pathophysio-
logical insults, such as sepsis. There are some similarities
between DIC and early traumatic coagulopathy, includ-
ing depleted coagulation factors and increased fibrinoly-
sis [27, 34]. However, histological examination did not
show disseminated clot formation in trauma patients
[88]. The underlying mechanisms contributing to the de-
velopment of sepsis DIC and trauma-induced coagulopa-
thy remain unclear.
Conclusion
Coagulation complications after trauma have been con-
sidered to be attributed to hypothermia, acidosis and
hemodilution from blood loss and resuscitation. Clin-
ical findings over the last decade have expanded our
knowledge of this topic to shortly after trauma injury.
Hemostatic manifestations may be present at hospital
admission in some severely injured trauma patients,
with mortality 3 to 4 times higher than those without
coagulation complications. This recognition has led to
the use of new terminology and the generation of some
hypotheses in the trauma community. However, the
underlying mechanisms related to the development of
coagulation complications after trauma remain unclear.
Continuing research effort and large clinical trials are
warranted to improve our understanding and to facili-
tate the search of effective treatments for coagulation
complications after trauma.
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